Target intelligence / Profile preview

Calcium channel, voltage-dependent, T-type, subunit alpha-1H (Cav3.2)

Target
Cav3.2
Molecular classification
Ion channel, Voltage-gated calcium channel, T-type calcium channel
01

Overview

The Cav3.2 T-type calcium channel (encoded by the CACNA1H gene) is a member of the voltage-gated calcium channel family characterized by low-voltage activation and transient kinetics[1][2]. It consists of a single pore-forming alpha-1H subunit that permits the influx of calcium ions in response to membrane depolarization, regulating neuronal excitability and secretory functions. Cav3.2 channels are found throughout the nervous system, heart, endocrine glands, and other excitable tissues[1][2][3]. They play pivotal roles in synaptic transmission, pacemaking activities, pain pathways, and hormone release[1][3][6]. Cav3.2 upregulation is associated with various disease states, particularly neuropathic pain, epilepsy, and hormone-related disorders. Selective pharmacological inhibition of Cav3.2 is a key therapeutic strategy under investigation for chronic pain and other indications, although safety and selectivity considerations remain critical challenges[3][6].

Other names
Cav3.2alpha-1H subunitCACNA1HT-type calcium channel α1H
02

Mechanism of action

Inhibition/blockade of Cav3.2 reduces pain signaling and neuronal excitability[3]. Drugs can block calcium entry by binding pore-forming subunit or modulating channel gating[3].

03

Biological functions

Neuronal excitability regulationPacemaking activity in the heartSecretion of hormones and neurotransmittersAmplification of dendritic excitatory postsynaptic potentialsMaintenance of circadian rhythmsSignal transduction
04

Disease associations

Pain (acute and chronic, including neuropathic pain)Epilepsy (absence epilepsy)Parkinson's diseaseCancerCardiovascular diseaseEndocrine disorders (including roles in aldosterone production in adrenal adenomas)
05

Safety considerations

Potential for cardiac effects due to roles in pacemakingBroad expression may lead to off-target central nervous system and hormonal side effects[3][6]Challenges with selectivity (distinguishing Cav3.2 from similar calcium channels)[3]Previous drugs targeting this channel (e.g., mibefradil) were withdrawn due to adverse effects[3]
06

Interacting drugs

Mibefradil (historical, withdrawn)

3 more in the full profile.

07

Biomarkers

Increased Cav3.2 expression in dorsal root ganglia is a biomarker for chronic neuropathic pain[4]Upregulation in adrenal adenomas correlates with high aldosterone levels[5]Cardiac/neural tissue expression profiles are used for disease association[6]

Beyond the preview

Go deeper on Calcium channel, voltage-dependent, T-type, subunit alpha-1H (Cav3.2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcium channel, voltage-dependent, T-type, subunit alpha-1H (Cav3.2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call